Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS.

Blood advances - 11 Jul 2023

Stengel Anna, Haferlach Torsten, Baer Constance, Hutter Stephan, Meggendorfer Manja, Kern Wolfgang, Haferlach Claudia

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 36735768
DOI: 10.1182/bloodadvances.2022009100
PMCID: PMC10320211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS.PMID 36735768Read ↗

Therapy-related myeloid neoplasms with single-hit TP53 mutations share the clinical, molecular, and survival characteristics of their multi-hit counterparts.Semantic proximity Read ↗

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDSSemantic proximity Read ↗

Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapySemantic proximity Read ↗

Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.Semantic proximity Read ↗

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.Semantic proximity Read ↗

TP53 in MDS and AML: Biological and clinical advances.Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.Semantic proximity Read ↗

Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.Semantic proximity Read ↗

Overall survival in TP53-mutated AML and MDS.Semantic proximity Read ↗

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.